Track topics on Twitter Track topics that are important to you
Immuno-oncology company iOmx Therapeutics AG (Martinsried, Germany) raised EUR 40 million ($44.6 million) in a series A round co-led by MPM Capital and Sofinnova Partners. Other investors included Wellington Partners and the Merck Ventures subsidiary of Merck KGaA (Xetra:MRK).
The preclinical-stage biotech is developing antibodies against checkpoint targets found on tumors rather than immune cells. iOmx said its screens have identified about 20 such targets.
Original Article: iOmx raises EUR 40M series A roundNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...